(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Insane Realities That Will Make You Reconsider How you might interpret History- Instructions to Keep up with Your Traded Teeth for Life span
- Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank
- Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
- Extraordinary Snowboarding Objections All over the Planet
- Most loved Solace Food: What's Your Definitive Comfortable Dinner?
- NASA satellite gazes into Medusa Pool | Space photo of the day for Dec. 24, 2025
- Polish law aimed at lowering petrol prices takes effect
- Why the UAE has incurred the wrath of Somalia
